Accession Number:

ADA416652

Title:

Studies of a Ras Antagonist in Breast Cancer

Descriptive Note:

Annual rept. 8 Apr 2002-7 Apr 2003

Corporate Author:

VIRGINIA UNIV CHARLOTTESVILLE

Personal Author(s):

Report Date:

2003-05-01

Pagination or Media Count:

21.0

Abstract:

The aim of this project is preclinical testing of a novel Ras antagonist, farnesylthiosalicylate FTS in complex with a cyclodextrin CD carrier. Ras is involved in estrogen and growth factor signaling in breast cancer cells. inhibition of Ras should prevent growth of breast cancer cells. We have tested FTS-CD against several breast cancer cell lines in vitro and found that FTS-CD is effective against estrogen receptor positive breast cancer in vitro. FTS-CD is effective against Tamoxifen resistant cells in vitro. FTS-CD interferes with estrogen signaling. FTS-CD induces profound changes in cell signaling, manifested as increase in apoptosis and decrease in proliferation.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE